Navigation Links
China Medicine Releases White Paper on Developing Recombinant Aflatoxin-Detoxifizyme
Date:7/9/2008

GUANGZHOU, China, July 9 /Xinhua-PRNewswire/ -- China Medicine Corporation (OTC Bulletin Board: CHME; " China Medicine" or " the Company"), a leading distributor and developer of ethical and over-the-counter drugs, traditional Chinese Medicine (TCM), nutritional and dietary supplements, medical devices, and medical formulations in the People's Republic of China (PRC), announced today that it released a white paper on Recombinant Aflatoxin-Detoxifizyme ("rADTZ"). The paper describes the origin, development and history of rADTZ, its scientific basis, and its market potential in the feed, food and health care industries. The white paper is available for download on the Company's website: http://www.chinamedicinecorp.com/adtz.htm .

"We are very excited about the development of rADTZ, which has the potential to detoxify aflatoxin (AFT) in food and feed, and we are currently carrying out experiments on animal feed," said Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation. "We hope to bring you positive news on the results in the near future."

About China Medicine Corporation

China Medicine Corporation is a leading pharmaceutical company which discovers and develops medical formulations and distributes over 2,200 pharmaceutical products in China including prescription and over-the-counter drugs, traditional Chinese medicine products, herbs and dietary supplements. The Company distributes the products to wholesale distributors in 28 provinces and to more than 300 hospitals, 500 medicine companies, and 1,788 drug stores throughout China. The Company actively develops a number of proprietary products for many uses including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company's website at http://www.chinamedicinecorp.com .

Cautionary Statement

This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statement to reflect events or circumstances after the date of this release.

Company Contact:

Ms. Huizhen Yu

Chief Financial Officer

China Medicine Corp.

Tel: +86-20-8739-1718

Email: konzern08@163.com

Web: http://www.chinamedicinecorp.com

Investor Relations Contact:

Mr. Crocker Coulson, President

CCG Elite Investor Relations

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Mr. Richard Micchelli, Financial Writer

CCG Elite Investor Relations

Tel: +1-646-454-4516

Email: richard.micchelli@ccgir.com

Web: http://www.ccgelite.com


'/>"/>
SOURCE China Medicine Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Chindex International, Inc. Announces Receipt of Key Regulatory ApprovalsChina SFDA Certificates Received Include Intuitive Surgical daVinci S
2. China Improves Safety Management on Imported Foods in Preparation for Olympic Games
3. AMDL Signs Letter of Intent to Purchase China-Based Pharmaceutical Distribution Company
4. Cynosure Expands Presence in China with the Opening of Sales Office in Beijing
5. Golden Meditech Pioneers into Chinas Hospital Market
6. Chinas Leading Healthcare Market Player Records 200% Increase in Profits and Earnings
7. Thomson Reuters Introduces a New Solution to Boost Competitive Advantage in Chinas Generics and API Market
8. China Medicine Maintains Exclusive Rights to Distribute 2,300 Pharmaceutical Products
9. China Sky One Medical, Inc. Research Center Recognized by Heilongjiang Science and Technology Institute
10. China Yingxia International, Inc. Appoints Chief Financial Officer
11. China Sky One Medical, Inc. to Acquire Peng Lai Jin Chuang Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... 2017 , ... The Pennsylvania Athletic Trainers’ Society’s (PATS) Annual ... Convention Center on June 8-10. The weekend consisted of many educational presentations, ... scholarship presentations, and professional networking. , On Friday June 9th, PATS hosted ...
(Date:6/23/2017)... ... 2017 , ... The Rhode Island Quality Institute (RIQI) and ... Dashboards, an innovative new service enabling healthcare providers to proactively coordinate care and ... Dashboards provide near real-time data about patients admitted to and/or discharged from acute ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or from ... how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, ... symptoms of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when ... read it, and some people don't like it at all. FindaTopDoc took a look ... , Erotic literature can give readers a taste of their deepest, darkest fantasies and ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State ... 18 to 20. , The two-day conference is focused on advancing scientific knowledge ... improving patients’ lives and eliminating racial breast cancer-related disparities. The conference theme is ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 8, 2017  StatLab Medical Products ("StatLab" ... manufacturer of diagnostic supplies for the anatomic ... & Company LP ("Cressey & Company"), a ... growth-focused investment in the Company. Cressey & ... from selling shareholder, Prairie Capital, L.P., with ...
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
(Date:6/5/2017)... , June 5, 2017 The ... brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded ... Cincinnati Enquirer . Results are based on an ... in organizational health and workplace improvement. The survey measures several ... ...
Breaking Medicine Technology: